Status:
COMPLETED
Treatment of Patients With Nocturia
Lead Sponsor:
Serenity Pharmaceuticals, Inc.
Conditions:
Nocturia
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
Eligibility Criteria
Inclusion
- Male and female 50 years or older
- Nocturia of 6 or more months duration averaging 2 episodes or more per night
Exclusion
- CHF
- Diabetes
- Diabetes Insipidus
- Renal Insufficiency
- Hepatic Insufficiency
- Incontinence
- Illness requiring steroids
- Current or past urologic malignancy
- Nephrotic Syndrome
- Unexplained pelvic masses
- Urinary bladder neurological dysfunction
- Urinary bladder surgery or radiotherapy
- Sleep Apnea
- Pregnant or breast feeding
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
301 Patients enrolled
Trial Details
Trial ID
NCT00937859
Start Date
June 1 2009
End Date
July 1 2010
Last Update
September 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Piedmont Medical Research Assoc.
Winston-Salem, North Carolina, United States, 27103